{"id":3135,"date":"2015-04-07T09:49:44","date_gmt":"2015-04-07T01:49:44","guid":{"rendered":"http:\/\/wp.kmu.edu.tw\/rd\/?p=3135"},"modified":"2015-04-07T09:49:44","modified_gmt":"2015-04-07T01:49:44","slug":"%e7%a0%94%e7%a9%b6%e8%ab%96%e6%96%87%e5%88%86%e4%ba%ab-5","status":"publish","type":"post","link":"https:\/\/wp.kmu.edu.tw\/rd\/archives\/3135","title":{"rendered":"\u7814\u7a76\u8ad6\u6587\u5206\u4eab"},"content":{"rendered":"<p style=\"text-align: right\"><a href=\"http:\/\/wp.kmu.edu.tw\/rd\/archives\/3131\">\u56de\u7b2c0031\u671f\u4e3b\u9801<\/a><\/p>\n<h1><span style=\"font-size: x-large;color: #c10000\">\u4e00\u3001\u8ad6\u6587\u5206\u4eab<\/span><\/h1>\n<p><a name=\"PaperRes1\"><\/a><\/p>\n<ul>\n<li><span style=\"color: #3366ff\">\u984c\u76ee\uff1a<strong><br \/>\nPeginterferon alfa-2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 2 receiving haemodialysis: a randomised trial.<br \/>\n<\/strong><\/span><\/li>\n<li>\u4f5c\u8005\uff1aLiu, Chen-Hua; Liu, Chun-Jen; Huang, Chung-Feng(\u9644\u9662 \u8077\u696d\u75c5\u79d1 \u9ec3\u91e7\u5cf0); Lin, Jou-Wei; Dai, Chia-Yen(\u9644\u9662 \u809d\u81bd\u80f0\u5167\u79d1 \u6234\u5609\u8a00); Liang, Cheng-Chao; Huang, Jee-Fu(\u9644\u9662 \u809d\u81bd\u80f0\u5167\u79d1 \u9ec3\u5fd7\u5bcc); Hung, Peir-Haur; Tsai, Hung-Bin; Tsai, Meng-Kun; Lee, Chih-Yuan; Chen, Shih-I; Yang, Sheng-Shun; Su, Tung-Hung; Yang, Hung-Chih; Chen, Pei-Jer; Chen, Ding-Shinn; Chuang, Wan-Long(\u9644\u9662 \u809d\u81bd\u80f0\u5167\u79d1 \u838a\u842c\u9f8d); Yu, Ming-Lung(\u9644\u9662 \u809d\u81bd\u80f0\u5167\u79d1 \u4f59\u660e\u9686); Kao, Jia-Horng.<br \/>\nGut. 2015 Feb;64(2):303-11. doi: 10.1136\/gutjnl-2014-307080. Epub 2014 Apr 19.\n<\/li>\n<\/ul>\n<ul>\n<li>\u6458\u8981\uff1a<br \/>\nOBJECTIVE: Data comparing the efficacy and safety of combination therapy with peginterferon plus low-dose ribavirin and peginterferon monotherapy in treatment-naive haemodialysis patients with hepatitis C virus genotype 2 (HCV-2) infection are limited.<br \/>\nDESIGN: In this randomised trial, 172 patients received 24 weeks of peginterferon alfa-2a 135 \u03bcg\/week plus ribavirin 200 mg\/day (n=86) or peginterferon alfa-2a 135 \u03bcg\/week (n=86). The efficacy and safety endpoints were sustained virological response (SVR) rate and adverse event (AE)-related withdrawal rate.<br \/>\nRESULTS: Compared with monotherapy, combination therapy had a greater SVR rate (74% vs 44%, relative risk (RR): 1.68 [95% CI 1.29 to 2.20]; p&lt;0.001). The beneficial effect of combination therapy was more pronounced in patients with baseline viral load \u2265800,000 IU\/mL than those with baseline viral load &lt;800,000 IU\/mL (RR: 3.08 [95% CI 1.80 to 5.29] vs. RR: 1.11 [95% CI 0.83 to 1.45]; interaction p=0.001). Patients receiving combination therapy were more likely to have a haemoglobin level of &lt;8.5 g\/dL (70% vs. 8%, risk difference (RD): 62% [95% CI 50% to 73%]; p&lt;0.001) and required a higher dosage [mean: 13,417 vs. 6667 IU\/week, p=0.027] of epoetin \u03b2 to manage anaemia than those receiving monotherapy. The AE-related withdrawal rates were 6% and 3% in combination therapy and monotherapy groups, respectively (RD: 2% [95% CI -4% to 9%]).<br \/>\nCONCLUSIONS: In treatment-naive haemodialysis patients with HCV-2 infection, combination therapy with peginterferon plus low-dose ribavirin achieved a greater SVR rate than peginterferon monotherapy. Most haemodialysis patients can tolerate combination therapy.<\/p>\n<\/li>\n<\/ul>\n<p><a name=\"PaperRes2\"><\/a><\/p>\n<ul>\n<li><span style=\"color: #3366ff\">\u984c\u76ee\uff1a<strong><br \/>\nEnhanced reactive oxygen species overexpression by CuO nanoparticles in poorly differentiated hepatocellular carcinoma cells<br \/>\n<\/strong><\/span><\/li>\n<\/ul>\n<ul>\n<li>\u4f5c\u8005\uff1aKung, Mei-Lang; Hsieh, Shu-Ling; Wu, Chih-Chung; Chu, Tian-Huei; Lin, Yu-Chun; Yeh, Bi-Wen; Hsieh, Shuchen(\u85e5\u5b78\u7cfb \u8b1d\u6dd1\u8c9e)<br \/>\nNanoscale, 2015, 7, 1820-1829\n<\/li>\n<\/ul>\n<ul>\n<li>\u6458\u8981\uff1a<br \/>\nCopper oxide nanoparticles (CuO NPs) are known to exhibit toxic effects on a variety of cell types and organs. To determine the oxidative impact of CuO NPs on hepatocellular carcinoma (HCC) cells, well-differentiated (HepG2) and poorly differentiated (SK-Hep-1) cells were exposed to CuO NPs. Cell viability assay showed that the median inhibition concentration (IC50) for SK-Hep-1 and HepG2 cells was 25 \u03bcg ml\u22121 and 85 \u03bcg ml\u22121, respectively. Cellular fluorescence intensity using DCFH-DA staining analysis revealed significant intracellular reactive oxygen species (ROS) generation of up to 242% in SK-Hep-1 cells, compared with 86% in HepG2 cells. HPLC analysis demonstrated that a CuO NP treatment caused cellular GSH depletion of 58% and a GSH\/GSSG ratio decrease to [similar]0.1 in SK-Hep-1 cells. The oxidative stress caused by enhanced superoxide anion production was observed in both HepG2 (146%) and SK-Hep-1 (192%) cells. The Griess assay verified that CuO NPs induced NO production (170%) in SK-Hep-1 cells. Comet assay and western blot further demonstrated that CuO NPs induced severe DNA strand breakage (70%) in SK-Hep-1 cells and caused DNA damage via increased \u03b3-H2AX levels. These results suggest that well-differentiated HepG2 cells possess a robust antioxidant defense system against CuO NP-induced ROS stress and exhibit more tolerance to oxidative stress. Conversely, poorly differentiated SK-Hep-1 cells exhibited a deregulated antioxidant defense system that allowed accumulation of CuO NP-induced ROS and resulted in severe cytotoxicity.<\/li>\n<\/ul>\n<p style=\"text-align: right\"><a href=\"http:\/\/wp.kmu.edu.tw\/rd\/archives\/3131\">\u56de\u7b2c0031\u671f\u4e3b\u9801<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>\u56de\u7b2c0031\u671f\u4e3b\u9801 \u4e00\u3001\u8ad6\u6587\u5206\u4eab \u984c\u76ee\uff1a Peginterferon alfa- &hellip; <a href=\"https:\/\/wp.kmu.edu.tw\/rd\/archives\/3135\">\u95b1\u8b80\u5168\u6587 <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"footnotes":""},"categories":[39],"tags":[],"class_list":["post-3135","post","type-post","status-publish","format-standard","hentry","category-39"],"_links":{"self":[{"href":"https:\/\/wp.kmu.edu.tw\/rd\/wp-json\/wp\/v2\/posts\/3135","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/wp.kmu.edu.tw\/rd\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/wp.kmu.edu.tw\/rd\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/wp.kmu.edu.tw\/rd\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/wp.kmu.edu.tw\/rd\/wp-json\/wp\/v2\/comments?post=3135"}],"version-history":[{"count":1,"href":"https:\/\/wp.kmu.edu.tw\/rd\/wp-json\/wp\/v2\/posts\/3135\/revisions"}],"predecessor-version":[{"id":3136,"href":"https:\/\/wp.kmu.edu.tw\/rd\/wp-json\/wp\/v2\/posts\/3135\/revisions\/3136"}],"wp:attachment":[{"href":"https:\/\/wp.kmu.edu.tw\/rd\/wp-json\/wp\/v2\/media?parent=3135"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/wp.kmu.edu.tw\/rd\/wp-json\/wp\/v2\/categories?post=3135"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/wp.kmu.edu.tw\/rd\/wp-json\/wp\/v2\/tags?post=3135"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}